曲普瑞林对乳腺癌化疗患者卵巢储备功能的影响研究

东辉 任(河北省承德市第三医院肿瘤外科，中国)
菲菲 刘(河北省承德市第三医院肿瘤外科，中国)
庆坤 孟(河北省承德市第三医院肿瘤外科，中国)
向东 左(河北省承德市第三医院肿瘤外科，中国)
凯华 于(河北省承德市第三医院肿瘤外科，中国)

摘要

本研究旨在探讨曲普瑞林辅助治疗乳腺癌化疗患者对卵巢储备功能的影响。研究选取200例符合标准的乳腺癌患者，将其分为观察组与对照组，观察组接受曲普瑞林辅助治疗，对照组则未接受。研究对比了两组患者化疗前后卵巢储备功能相关指标及不良反应数据。化疗前，两组AMH、FSH、E2水平无显著差异（P>0.05）。化疗后，观察组AMH水平为（2.5±0.4）ng/mL，显著高于对照组的（1.8±0.3）ng/mL（P<0.05）；观察组FSH升高幅度显著低于对照组（P<0.05）；观察组E2水平为（30.0±4.0）pg/mL，显著高于对照组的（20.0±3.0）pg/mL（P<0.05）。由此可见，曲普瑞林辅助治疗对乳腺癌患者卵巢储备功能具有一定保护作用。而在药物不良反应方面，两组在贫血、白细胞下降、疲劳、脱发、恶心等发生率上均无显著差异（P>0.05）。

关键词

曲普瑞林；卵巢；乳腺癌；化疗

参考

Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. Published online February 24, 2025.

Guida JL, Green P, Clague-DeHart J, et al. The Health of Women (HOW) Study®: a web-based survey of breast cancer risk factors, diagnosis, and treatment. J Cancer Surviv. 2023;17(5):1445-1451.

Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19(14):3306-3311.

Zhao D, Ma Q, Li G, Qin R, Meng Y, Li P. Treatment-induced menopause symptoms among women with breast cancer undergoing chemotherapy in China: a comparison to age- and menopause status-matched controls. Menopause. 2024;31(2):145-153.

Zhang S, Liu Q, Chang M, et al. Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis. Cell Death Dis. 2023;14(5):340. Published 2023 May 24.

Bahmanpour S, Ameri N, Zareifard N, Karimi F. The Protective Effect of GnRH Agonist Triptorelin on the Histomorphometric Parameters of the Utero-ovarian Tissue in the Doxorubicin- and Cyclophosphamide-treated Mice. Cell Biochem Biophys. 2025;83(1):573-586.

Yildiz S, Bildik G, Benlioglu C, et al. Breast cancer treatment and ovarian function. Reprod Biomed Online. 2023;46(2):313-331.

Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269-276. doi:10.1001/jama.2011.991

Torrisi R, Basilico V, Giordano L, et al. Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy? Breast Care (Basel). 2022;17(1):10-15. doi:10.1159/000514445

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v8i2.24027